Status:
COMPLETED
Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)
Lead Sponsor:
MJM Bonten
Collaborating Sponsors:
Janssen Research & Development, LLC
Innovative Medicines Initiative
Conditions:
E.Coli Infections
Eligibility:
All Genders
60+ years
Brief Summary
The purpose of this study is to collect information from study participants who develop an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC) during a period of 12 months. This info...
Detailed Description
Invasive ExPEC disease (IED) is defined as an acute illness consistent with bacterial infection that is microbiologically confirmed by the isolation and identification of E. coli from blood or other n...
Eligibility Criteria
Inclusion
- Participant is willing to provide written informed consent prior to inclusion.
- Participant is male or female preferably with a history of UTI in the previous 10 years. Participant without a (known) history of UTI in the previous ten years may also be enrolled.
- Participant is aged 60 years or older on the day of signing the informed consent form (ICF).
- Participant is willing to be available for contact with investigator for the duration of the study.
- Participant is ambulatory and lives in the community or in assisted-living or long-term care residential facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.
- Based on the clinical judgment of the investigator, participant must be in stable health. Participants may have underlying illnesses such as hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), type 2 diabetes mellitus, as long as their signs and symptoms are stable and medically controlled.
Exclusion
- Participant has a serious chronic disorder, including severe COPD or clinically significant CHF, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g. compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments.
- Participant has history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence).
- Participant has had major psychiatric illness and/or drug or alcohol abuse which in investigators opinion would compromise the participant's safety and/or compliance with the study procedures.
- Participant who, in the opinion of the investigator, is unlikely to adhere to the requirements of the study, or is unlikely to complete the full course of the study.
Key Trial Info
Start Date :
September 28 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 21 2021
Estimated Enrollment :
4479 Patients enrolled
Trial Details
Trial ID
NCT04087681
Start Date
September 28 2019
End Date
June 21 2021
Last Update
September 21 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Clinical Research Institute
Durham, North Carolina, United States, 27701
2
Duke Clinical Research Institute
Greater Sudbury, Canada
3
Chu Limoges - Cic
Limoges, France, 87042
4
UKK Uniclinic Cologne
Cologne, Germany, 50937